Erratum: Isatuximab Subcutaneous by On-Body Injector Versus Isatuximab Intravenous Plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Phase III IRAKLIA Study

Sikander Ailawadhi

17Department of Hematology and Medical Oncology, Mayo Clinic, Jacksonville, FL

Ivan Špička

9Charles University and General Faculty Hospital in Prague, Prague, Czech Republic

Andrew Spencer

Jin Lu

Center for Biological Physics, Arizona State University

Albert Oriol

Institut Català d’Oncologia and Institut Josep Carreras, Hospital Germans Trias i Pujol, Badalona, Spain

Silvia Ling

Fredrik Schjesvold

Alejandro Berkovits

3Inmunocel, Santiago, Chile

Marek Hus

Chunrui Li

3Department of Hematology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Meletios-Athanasios Dimopoulos

1Department of Clinical Therapeutics, School of Medicine, National and Kapodistrian University of Athens, Athens, Greece

Peter Rajnics

15Mór Kaposi Teaching Hospital, Kaposvár, Hungary

Sevgi Kalayoğlu Beşışık

13Department of Internal Medicine, Istanbul Medical Faculty, Istanbul University, Istanbul, Turkey

Vania Hungria

Clinica São Germano, São Paulo

Maria del Rosario Custidiano

13Instituto Alexander Fleming, Buenos Aires, Argentina

Gurdeep Parmar

10Illawarra Cancer Care Centre, Wollongong, NSW, Australia

Xavier Leleu

Service Hématologie, Hôpital Universitaire de Poitiers, Poitiers, France

Fei Li

Claudio Cerchione

Cesar Gomez

5Norfolk and Norwich University Hospitals, Norwich, United Kingdom

Tadao Ishida

Japanese Red Cross Medical Center, Tokyo

Maria Victoria Mateos

Hospital Universitario de Salamanca, Instituto de Investigación Biomédica de Salamanca, Instituto de Biología Molecular y Celular del Cáncer (Universidad de Salamanca–Consejo Superior de Investigaciones Científicas), Centro de Investigación Biomédica en Red de Cáncer, Salamanca, Spain

Tondre T. Buck

Spartanburg Medical Center, Center for Hematology/Oncology, Spartanburg, SC

Richard LeBlanc

Jiri Minarik

1Palacky University and University Hospital Olomouc, Olomouc, Czech Republic

Hartmut Goldschmidt

Internal Medicine V, Hematology, Oncology and Rheumatology, German-Speaking Myeloma Multicenter Group Study Group, Heidelberg University Hospital and National Center for Tumor Diseases, Heidelberg, Germany

Rick Zhang

22Sanofi, Morristown, United States

Dorothee Semiond

23Sanofi, Cambridge, United States

Florence Suzan

Sanofi Research & Development, Vitry-Sur-Seine, France

Maya Stefanova-Urena

22Sanofi, Morristown, United States

Victorine Koch

21Sanofi, Vitry-sur-Seine, France

Philippe Moreau